Key facts
- It has raised $2.7M; the latest was Later Stage VC ($2.7M) in Dec 2025.
- Notable investors include Tech Incubator Program for Startup, Seoul National University Technology Holdings, Ray (Healthcare technology), Yeonsei Technology Holdings, iAccel (Seongnam-si).
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for CellArtgen
- ·The full record, as it builds
Funding rounds
No funding rounds for CellArtgen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CellArtgen
Developer of regenerative therapeutics designed to treat diseases by replacing tissues and organs of the human body. The company's therapeutics reflect the genetic characteristics of each tissue that makes up the actual organ, and the arrangement of cells is similar to that of a real organ, enabling healthcare professionals to potentially treat nonalcoholic steatohepatitis, Alzheimer's disease, and pulmonary fibrosis.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2020
- Employees
- 21
- Website
- cellartgen.com/kor/main
- Ownership
- Privately Held (backing)
CellArtgen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CellArtgen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CellArtgen in its N-PORT filings yet. We sweep new filings monthly.